Chief Executive Officer

Co-Founder and Chief Science Officer

The ADDF's Diagnostics Accelerator Unveils SpeechDx Dataset and New Partnership to Catalyze Breakthroughs in Speech-Based Biomarkers

FDA Approval of Leqembi Subcutaneous Formulation Charts Path to Combination Therapies for Alzheimer's Disease

Transposon Shepherding Potential Treatment for ALS, Alzheimer’s

New Alzheimer's Clinical Guidelines Move Towards Replacing More Invasive Tools with Blood Tests; Pressing Need for Further Guidance Remains

Assistant Director, SpeechDx

The Alzheimer's Drug Discovery Foundation is dedicated to accelerating the discovery of drugs for Alzheimer's disease. The Assistant Director, SpeechDx will lead all operational aspects of a global clinical research study focused on AI-enabled Alzheimer's research, ensuring alignment with scientific priorities and managing day-to-day study logistics.

Sign up with Google

Sign in with Google